BOC Sciences provides unparalleled expertise in antibody-drug conjugate (ADC) production. Besides cysteine conjugation, lysine conjugation, carbohydrate conjugation, unnatural amino acids conjugation of these ADC with production methods, we also provide other coupling method, including enzymatic modified antibody, etc. BOC Sciences has established a one-stop integrated antibody and drug platform to provide you with antibody engineering and conjugation services.
Enzymatic modified antibodies can be used for site-specific coupling. In this approach, enzymes that recognize specific amino acid markers are developed for site-specific antibody coupling. Transglutaminase is an enzyme that catalyzes the transacylation of acyl groups leading to covalent cross-linking between proteins (or polypeptides). A bacterial transglutaminase (BTG) that recognizes only the Q295 position of the Fc region on deglycosyl IgGs, which reacts with a substrate with an amino group, and the ratio of substrate to antibody is accurate to 2:1.
Glycotransferase is a large family of proteins involved in the synthesis of oligosaccharides that are responsible for the transfer of glycosyl residues on activated sugar nucleotides to glycoconjugates or glycoproteins/liposomes. XXX can also synthesize site-specific antibody-drug conjugates via glycosyltransferase. The method utilizes a mutated glycosyl group to attach a chemically active glycosyl group to a position at which an antibody can undergo a glycosylation reaction, and then site-coupled with a drug molecule to generate ADCs.
As a global biotechnology company, BOC Sciences is able to design and implement the most appropriate coupling strategy to develop ADC. Our team of professionals and years of experience in the manufacture of therapeutic agents have enabled us to help you study the scientific and clinical uses of ADC.